IP Library Granted Patent US 10,788,486
Granted Patent B2
US 10,788,486 · App. 15/728,155 · Granted Sep 29, 2020

Graphene oxide-based nanolab and methods of detecting of exosomes

Inventors: Peng Zhang (Lawrence, KS); Yong Zeng (Olathe, KS); Mei He (Manhattan, KS)
Assignees: The University of Kansas; Kansas State University Research Foundation
G01N33/54393B01L3/502707B01L3/502761G01N33/54326G01N33/54353G01N33/6872B01L2200/0631B01L2200/0647B01L2300/0636B01L2300/0816B01L2300/0887
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,788,486
App. No.
15/728,155
Granted
Sep 29, 2020
Kind
B2
Abstract

A capture device for capturing a biological substance can include: a substrate; a graphene-oxide layer on the substrate; at least one polydopamine polymer coupled with the graphene-oxide; and at least one targeting receptor coupled to the polydopamine(s), wherein the targeting receptor is capable of targeting/binding with a target biological substance. The graphene-oxide may be covalently coupled with the substrate and polydopamine, and the polydopamine may be covalently coupled with the targeting receptor. The targeting receptor can be an antibody or fragment thereof. The target biological substance can be an exosome. The substrate can be a particle (e.g., magnetic, such as magnetically responsive) or a surface in a microfluidic channel. The surface can be a top surface of a post, the post having a Y-shaped cross-sectional profile. In one aspect, the substrate is a particle. The capture device can include the target biological substance bound to the targeting receptor.

Claims (34)

1. A graphene-oxide coated particle for capturing a biological substance, the particle comprising:

a core particle having a surface;

a graphene-oxide-layer coating said core particle, said graphene-oxide layer comprising graphene-oxide nanosheets, said graphene-oxide nanosheets being covalently bonded to the particle surface;

at least one polydopamine polymer coupled with the graphene-oxide nanosheets; and

at least one targeting receptor coupled to the at least one polydopamine polymer, wherein the targeting receptor is capable of targeting and binding with a target biological sub stance.

2. The graphene-oxide coated particle of claim 1 , wherein the core particle includes a functional group covalently coupled with a functional group of the graphene-oxide layer to form the covalent bond between the surface and graphene-oxide nanosheets.

3. The graphene-oxide coated particle of claim 1 , wherein the graphene-oxide nanosheets include a functional group that is covalently coupled with a functional group of the at least one polydopamine polymer to form a covalent bond between the graphene-oxide nanosheets and polydopamine polymer.

4. The graphene-oxide coated particle of claim 1 , wherein the at least one polydopamine polymer includes a functional group that is covalently coupled with a functional group of the at least one targeting receptor to form a covalent bond between the polydopamine polymer and targeting receptor.

5. The graphene-oxide coated particle of claim 1 , wherein the targeting receptor is an antibody or fragment thereof.

6. The graphene-oxide coated particle of claim 1 , wherein the target biological substance is an exosome.

7. The graphene-oxide coated particle of claim 1 , wherein the core particle is a core/shell magnetic particle having a magnetic core and a functionalized shell.

8. The graphene-oxide coated particle of claim 1 , wherein

the graphene-oxide nanosheets are covalently bonded to the at least one polydopamine polymer; and wherein

the at least one polydopamine polymer is covalently bonded to the at least one targeting receptor.

9. The graphene-oxide coated particle of claim 1 , comprising the target biological substance bound to the targeting receptor.

10. The graphene-oxide coated particle of claim 1 , wherein said particle is a magnetic bead.

11. The graphene-oxide coated particle of claim 1 , wherein said graphene-oxide layer comprises a plurality of said graphene-oxide nanosheets covalently bonded to said substrate surface, said graphene-oxide nanosheets having a plurality of polydopamine polymers coupled thereto.

12. The graphene-oxide coated particle of claim 11 , wherein each polydopamine polymer extends from the graphene-oxide layer away from the particle.

13. The graphene-oxide coated particle of claim 11 , wherein said plurality of polydopamine polymers form a layer having a 3-dimensional, porous morphology on said graphene-oxide layer.

14. A method of capturing a target biological substance, the method comprising:

providing the graphene-oxide coated particle of claim 1 ; and

contacting a sample with the graphene-oxide coated particle such that the target biological substance associates with the targeting receptor.

15. The method of claim 14 , detecting the presence of the target biological substance being bound with the targeting receptor.

16. The method of claim 14 , comprising one of:

removing the graphene-oxide coated particle from the sample; or

removing the sample from the graphene-oxide coated particle.

17. The method of claim 14 , comprising dissociating the target biological substance from the targeting receptor.

18. The method of claim 15 , comprising qualitatively or quantitatively determining an amount or relative amount of the target biological substance in the sample.

19. A method of determining a disease state in a subject, the method comprising:

providing the graphene-oxide coated particle of claim 1 ;

obtaining a sample from the subject;

contacting the sample with the graphene-oxide coated particle;

and

detecting the presence of the target biological substance in the sample, wherein if the target biological substance binds with the targeting receptor, the target biological substance is present in the sample, or if the target biological substance does not bind with the targeting receptor, the target biological substance is absent in the sample to thereby determine the disease state in the subject.

Assignments (3)
CONFIRMATORY LICENSE Recorded Feb 27, 2018
From: UNIVERSITY OF KANSAS LAWRENCE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045464/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2017
From: HE, MEI
To: KANSAS STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 044218/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2017
From: ZHANG, PENG; ZENG, YONG
To: THE UNIVERSITY OF KANSAS
Reel/Frame 043884/0361 →
Continuity (2)
Provisional Application 62405927 · Oct 9, 2016
Related Publication 20180100853A1 · Apr 12, 2018